Shares of TapImmune, Inc. (OTCBB:TPIV) rose nearly 30% on Monday after the firm was mentioned positively by analysts reacting to recently published comments by Chairman & CEO Glynn Wilson, PH.D.
Wilson, in an exclusive interview with Life Sciences Intellectual Property Review estimates the Seattle-based company will be worth more than a $1 billion in just five years.
The U.K. Based Life Sciences Intellectual Property Review tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences.
Dirks Research, in a separate report released on Monday, said that an official announcement regarding the start of Phase II clinical trials for TapImmune’s immunotherapy cancer vaccines for Breast and Ovarian cancer is imminent.
Analysts also noted that a push of the company’s development pipeline into Phase II for two urgently needed therapeutic indications, each with blockbuster potential and huge market opportunities simultaneously, would likely create an inflection point in prices and valuation for the Seattle based firm.
In a recent quarterly filing, officials at TapImmune indicated that they planned to initiate the two pending Phase II studies in Q4 of 2014.
